Frydman R, Howles C M, Truong F
Hopital A. Beclère, Clamart.
Hum Reprod. 2000 Mar;15(3):520-5. doi: 10.1093/humrep/15.3.520.
This prospective, double-blind, randomized, multicentre study compared the efficacy and safety of recombinant human follicle stimulating hormone (r-hFSH; Gonal-F((R))) versus highly purified urinary FSH (u-hFSH HP; Metrodin((R)) HP) in women undergoing ovarian stimulation for in-vitro fertilization, including intracytoplasmic sperm injection. A total of 278 patients began a long gonadotrophin-releasing hormone agonist protocol, then 139 received r-hFSH and 139 u-hFSH HP, 150 IU/day administered s.c., for the first 6 days of treatment. On day 7, the dose was adjusted, if necessary, according to ovarian response. Human chorionic gonadotrophin (HCG, 10 000 IU, s.c.) was administered once there was more than one follicle 18 mm in diameter and two others >/=16 mm. Oocyte retrieval was performed 36-38 h after HCG injection: 128 patients (92%) receiving r-hFSH and 113 (81%) receiving u-hFSH HP had at least one oocyte retrieved. Among patients receiving r-hFSH, there was a significantly higher mean (+/- SD) number of oocytes retrieved (11.0 +/- 5.9 versus 8.8 +/- 4.8 with u-hFSH HP; P = 0. 002) and mean number of embryos obtained (5.1 +/- 3.7 versus 3.5 +/- 2.9 with u-hFSH HP; P = 0.0001). With r-hFSH, significantly fewer FSH treatment days (11.7 +/- 1.9 versus 14.5 +/- 3.3) and 75 IU ampoules (27.6 +/- 10.2 versus 40.7 +/- 13.6) were required than with u-hFSH HP (P = 0.0001). Embryo replacement on day 2-3 after oocyte retrieval resulted in 36 liveborn children in the Gonal-F((R)) group and 33 in the Metrodin HP((R)) group (not significant). There were seven cases (5.0%) of ovarian hyperstimulation syndrome in the r-hFSH group and three (2.2%), in the u-hFSH HP group (not significant). It is concluded that r-hFSH is more effective than u-hFSH in inducing multiple follicular development.
本前瞻性、双盲、随机、多中心研究比较了重组人促卵泡激素(r-hFSH;果纳芬(Gonal-F))与高纯度尿促卵泡素(u-hFSH HP;高纯度美诺孕(Metrodin HP))在接受体外受精(包括卵胞浆内单精子注射)卵巢刺激的女性中的疗效和安全性。共有278例患者开始采用长效促性腺激素释放激素激动剂方案,然后139例接受r-hFSH,139例接受u-hFSH HP,治疗的前6天皮下注射150 IU/天。在第7天,根据卵巢反应必要时调整剂量。一旦有一个以上直径18 mm的卵泡和另外两个直径≥16 mm的卵泡,即皮下注射人绒毛膜促性腺激素(HCG,10 000 IU)。在注射HCG后36 - 38小时进行取卵:接受r-hFSH的128例患者(92%)和接受u-hFSH HP的113例患者(81%)至少取到了一个卵母细胞。在接受r-hFSH的患者中,平均(±标准差)取到的卵母细胞数量显著更多(分别为11.0±5.9个和u-hFSH HP组的8.8±4.8个;P = 0.002),获得的胚胎平均数量也更多(分别为5.1±3.7个和u-hFSH HP组的3.5±2.9个;P = 0.0001)。与u-hFSH HP相比,使用r-hFSH时所需的FSH治疗天数显著更少(分别为11.7±1.9天和14.5±3.3天),75 IU安瓿数也显著更少(分别为27.6±10.2支和40.7±13.6支)(P = 0.0001)。在取卵后第2 - 3天进行胚胎移植,果纳芬组有36例活产婴儿,高纯度美诺孕组有33例活产婴儿(无显著差异)。r-hFSH组有7例(5.0%)发生卵巢过度刺激综合征,u-hFSH HP组有3例(2.2%)(无显著差异)。结论是,在诱导多个卵泡发育方面,r-hFSH比u-hFSH更有效。